





882

<b>TRANSMITTAL LETTER</b> <b>(General - Patent Pending)</b>				Docket No. <b>05900002AA</b>	
In Re Application Of: <b>D. Anderson</b>					
					
Application No. <b>09/994,937</b>	Filing Date <b>November 28, 2001</b>	Examiner <b>E. J. Webman</b>	Customer No. <b>30743</b>	Group Art Unit <b>1616</b>	Confirmation No. <b>7327</b>
Title: <b>SOLVENT SYSTEM FOR PHARMACEUTICAL AGENTS</b>					
<u>COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is:  <b>RESPONSE TO RESTRICTION REQUIREMENT WITH AMENDMENT</b>					
in the above identified application.					
<input checked="" type="checkbox"/> No additional fee is required.					
<input type="checkbox"/> A check in the amount of _____ is attached.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <b>50-2041</b> as described below.					
<input type="checkbox"/> Charge the amount of _____					
<input checked="" type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional fee required.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 _____ <i>Signature</i>			Dated: <b>May 9, 2005</b>		
Michael E. Whitham Reg No. 32,635 Whitham, Curtis & Christofferson, PC 11491 Sunset Hills Road, Suite 340 Reston, Virginia 20190 703-787-9400			<div>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</div> <div>_____ (Date)</div> <div>Signature of Person Mailing Correspondence</div> <div style="text-align:center"><b>HAND DELIVERED</b></div> <div>Typed or Printed Name of Person Mailing Correspondence</div>		
cc:					

<b>AMENDMENT TRANSMITTAL LETTER (Small Entity)</b>				Docket No. <b>05900002AA</b>	
Applicant(s): <b>D. Anderson</b>					
Application No. <b>09/994,937</b>	Filing Date <b>November 28, 2004</b>	Examiner <b>E. J. Webman</b>	Customer No. <b>30743</b>	Group Art Unit <b>1616</b>	Confirmation No. <b>7327</b>
Invention: <b>SOLVENT SYSTEM FOR PHARMACEUTICAL AGENTS</b>					
<u>COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application.					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	56 -	60 =	0	x \$25.00	\$0.00
INDEP. CLAIMS	4 -	5 =	0	x \$100.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>50-2041</b> <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 _____ Signature			Dated: <b>May 9, 2005</b>		
<b>Michael E. Whitham</b> <b>Reg no. 32,635</b> <b>Whitham, Curtis &amp; Christofferson, PC</b> <b>11491 Sunset Hills Road, Suite 340</b> <b>Reston, Virginia 20190</b> <b>703-787-9400</b>			<div style="border: 1px solid black; padding: 5px;">           I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____            (Date)         </div> <div style="border: 1px solid black; padding: 5px; text-align: center;"> <b>Signature of Person Mailing Correspondence</b>  <b>HAND DELIVERED</b>  <b>Typed or Printed Name of Person Mailing Correspondence</b> </div>		
cc:					



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

Anderson

Confirmation No. 7327

Serial No. 09/994,937

Group Art Unit 1616

Filed November 28, 2001

Examiner Edward Webman

For SOLVENT SYSTEMS FOR PHARMACEUTICAL AGENTS

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT  
WITH AMENDMENT

Sir:

In response to the Office Action mailed April 14, 2005, the applicant elects the "liquid crystalline phase" species of claim 2 (now canceled). To highlight this election, a number of claims have been amended to recite a liquid crystalline phase (alone or in combination with other phases) in the independent claims. All claims now pending read on the elected species.

Please amend the above-identified patent application as follows:

**Amendments to the Claims:** Amendments to the claims are indicated by the notation "currently amended" in the listing of claims beginning on page 2 of this paper.

**Remarks:** The "REMARKS" section begins on page 14 of this paper.